Showing papers by "Peter MacCallum Cancer Centre published in 1991"
Journal Article•
TL;DR: The Philadelphia chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML) and as such has been used to confirm the diagnosis of CML based on morphological and clinical criteria and in six of the 12 patients, rearrangement within the 5.8 kb major breakpoint region (M-bcr) and amplification of C ML specific M- bcr-ABL cDNA sequences by the polymerase chain reaction (PCR) was demonstrated.
Abstract: The Philadelphia chromosome (Ph) is the cytogenetic hallmark of chronic myeloid leukemia (CML) and as such has been used to confirm the diagnosis of CML based on morphological and clinical criteria. We have investigated 12 patients who were considered to have clinical and morphological features of CML and who did not have detectable abnormalities of chromosomes 9q34 or 22q11. In six of the 12 patients, rearrangement within the 5.8 kb major breakpoint region (M-bcr) and amplification of CML specific M-bcr-ABL cDNA sequences by the polymerase chain reaction (PCR) was demonstrated. Six other CML patients did not have rearrangement of the M-bcr gene or amplification of BCR-ABL by PCR. These patients had atypical CML. They were significantly older, most had less than 10% immature granulocytic cells (metamyelocytes, myelocytes and promyelocytes) and had various degrees of marrow fibrosis. Three of these six patients died of blastic transformation at 4, 15 and 54 months from diagnosis.
31 citations
Journal Article•
TL;DR: It is concluded that maturation of megakaryocytes occurs in long-term marrow culture to the point where platelet release appears imminent, and final rupture is rare and may require shearing forces, which in vivo would be provided by blood flow.
17 citations
TL;DR: Hodgkin's disease limited to the infradiaphragmatic region was seen in 30 of 306 patients referred to the Peter MacCallum Cancer Institute between 1968 and 1980 and the five and ten-year survival was 75% and 67% respectively.
Abstract:
Hodgkin's disease limited to the infradiaphragmatic region was seen in 30 of 306 (9.8%) of all Stage I and II patients referred to the Peter MacCallum Cancer Institute between 1968 and 1980. The male:female ratio was 2.3:1 with median age of 43.5 years at presentation.
Of the seven patients with clinical stage (CS) IA-IIA disease who had staging laparotomy and splenectomy only one CSIIA patient had splenic involvement. The patients were staged as pathological stage (PS) IA 2, PSIIA 5, CSIA 4, CSIIA 10, CSIIB 9.
Primary treatment was by radiation in 24 patients, combination chemotherapy in five and surgical excision in one. Twenty-five patients achieved complete response. Relapse free survival (RFS) at five and ten years was 59% and the five and ten-year survival was 75% and 67% respectively.
On univariate analysis the significant prognostic factors for RFS and survival were stage, constitutional symptoms and presence of bulky disease.
Using Cox regression analysis the only significant variable for RFS and survival was bulky disease (p= 0.01, 0.02).
A treatment policy for patients with infradiaphragmatic Hodgkin's disease is recommended.
11 citations